Drug Trial Radar · NCT05270213
Evaluation of RBS2418 in Subjects With Advanced, Metastatic Solid Tumors
Last checked: Nov 19, 2026Latest source record: Dec 19, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
164
Planned (sponsor's estimate)
Start
Jul 11, 2022
Primary completion
Apr 2027
Study completion Dec 2027
Sponsor
- Lead sponsor
- Riboscience, LLC.Industry
- Sponsor type
- Industry
- First posted
- Mar 8, 2022
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Non randomized
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
RBS2418 (investigational product) is a specific immune modulator, working through ectonucleotide pyrophosphatase/phosphodiesterase I (ENPP1), designed to lead to anti-tumor immunity by increasing endogenous 2'-3'-cyclic guanosine monophosphate-adenosine monophosphate (cGAMP) and adenosine triphosphate (ATP levels) and reducing adenosine production in the tumors. RBS2418 has the potential to be an important therapeutic option for subjects both as monotherapy and in combination with other cancer treatments including monotherapy and in combination with other cancer treatments including immunotherapy or chemotherapy. This study is an open-label, multi-site Phase 1a/1b study of RBS2418, a selective ENPP1 inhibitor, in combination with pembrolizumab or other approved anticancer therapies or as a monotherapy in subjects with advanced unresectable, recurrent or metastatic tumors. The phase 1a (dose escalation phase) has been completed. The Phase 1b expansion phase of the study has been increased in size and scope.
Conditions
- Advanced Cancer
Interventions
RBS2418Drug
RBS2418 is a potent and selective small molecule inhibitor of ectonucleotide pyrophosphatase/phosphodiesterase I (ENPP1). RBS2418 as monotherapy potentially can have an activating effect on the anti-tumor innate immune response and lead to anti-tumor responses in adult subjects with advanced or metastatic tumors.
PembrolizumabDrug
200 mg intravenously every 3 weeks
Other approved anti-cancer therapyDrug
Standard of care (SOC) therapy
Primary outcomes
What the sponsor says the trial is designed to measure.
- Treatment emergent dose limiting toxicities (DLT)Time frame: From 1- 21 days of the first cycle (each cycle is 21 days)
- Peak plasma concentration (Cmax) of RBS2418Time frame: Day 0 - 5
- Area under the plasma concentration versus time curve (AUC)Time frame: Day 0 - 5
- Optimal Biologically Active Dose (OBA)Time frame: Day 0 - 5
- Half-life (t1/2)Time frame: Day 0 - 5
- Number of participants with treatment emergent Adverse eventsTime frame: 30 days from last dose
Locations
14 sites in 1 country. Site status is shown where the registry gives one.
Honor Health Research Institute
Scottsdale, Arizona · Recruiting
University of Arizona
Tucson, Arizona · Recruiting
Stanford Cancer Institute
Palo Alto, California · Recruiting
UCLA Hematology/Oncology - Santa Monica
Santa Monica, California · Recruiting
Christiana Care Health Services
Newark, Delaware · Recruiting
Norton Cancer Institute
Louisville, Kentucky · Recruiting
Ochsner Clinic Foundation
New Orleans, Louisiana · Recruiting
Johns Hopkins Sidney Kimmel Comprehensive Cancer Center
Baltimore, Maryland · Recruiting
American Oncology Partners of Maryland
Bethesda, Maryland · Recruiting
Ichan School of Medicine at Mount Sinai
New York, New York · Recruiting
Carolina BioOncology Institute
Huntersville, North Carolina · Completed
Vanderbilt-Ingram Cancer Center
Nashville, Tennessee · Recruiting
Tranquil Research
Webster, Texas · Withdrawn
NEXT Virigina
Fairfax, Virginia · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.